Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

Related Citations for PubMed (Select 21814165)

2.

Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.

3.

Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):273.

4.

Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):72-6.

5.

Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.

MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC; Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC.

MMWR Morb Mortal Wkly Rep. 2014 Jun 20;63(24):527-30.

6.

Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2013 Jan 25;62(3):52-4.

8.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group.

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

9.

Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.

Cooper B, DeTora L, Stoddard J.

Expert Rev Vaccines. 2011 Jan;10(1):21-33. doi: 10.1586/erv.10.147. Review.

PMID:
21162617
10.

Meningococcal conjugate vaccines policy update: booster dose recommendations.

Committee on Infectious Diseases.

Pediatrics. 2011 Dec;128(6):1213-8. doi: 10.1542/peds.2011-2380. Epub 2011 Nov 28.

11.
12.

Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2005 May 27;54(RR-7):1-21.

13.

Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.

Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P.

J Pediatr. 2014 Jun;164(6):1409-15.e4. doi: 10.1016/j.jpeds.2014.02.025. Epub 2014 Mar 20.

PMID:
24657122
15.

Use of meningococcal vaccines in the United States.

Bilukha O, Messonnier N, Fischer M.

Pediatr Infect Dis J. 2007 May;26(5):371-6. Review.

PMID:
17468644
16.

Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).

Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV; Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34.

17.

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.

Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM.

Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.

18.

Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1023-5.

19.

Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.

Macneil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners.

Pediatr Infect Dis J. 2011 Jun;30(6):451-5. doi: 10.1097/INF.0b013e31820a8b3c.

PMID:
21206392
20.

Use of MenACWY-CRM in adolescents in the United States.

Black S, Block SL.

J Adolesc Health. 2013 Mar;52(3):271-7. doi: 10.1016/j.jadohealth.2012.07.017. Epub 2012 Sep 25. Review.

PMID:
23299001
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk